Thesis

17 Introduction REFERENCES 1. Prince MJ, Wimo A, Guerchet MM, Ali GC, Wu Y-T, Prina M. World Alzheimer Report 2015The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends. 2015. 2. Slot RE, Sikkes SA, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer’s disease and non–Alzheimer’s disease dementia. Alzheimer’s & Dementia. 2019;15:465-76. 3. Snitz BE, Wang T, Cloonan YK, Jacobsen E, Chang C-CH, Hughes TF, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimer’s & Dementia. 2018;14:734-42. 4. Jessen F, Amariglio RE, Van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s & dementia. 2014;10:844-52. 5. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Focus. 2013;11:96-106. 6. Graff-Radford J, Yong KX, Apostolova LG, Bouwman FH, Carrillo M, Dickerson BC, et al. New insights into atypical Alzheimer’s disease in the era of biomarkers. The Lancet Neurology. 2021;20:222-34. 7. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184-5. 8. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO molecular medicine. 2016;8:595-608. 9. van der Kant R, Goldstein LS, Ossenkoppele R. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience. 2020;21:21-35. 10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991;82:239-59. 11. Jack Jr CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia. 2018;14:535-62. 12. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic & medicinal chemistry letters. 2002;12:295-8. 13. Klunk WE, Wang Y, Huang G-f, Debnath ML, Holt DP, Shao L, et al. The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. Journal of Neuroscience. 2003;23:2086-92. 14. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound‐B. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 2004;55:30619. 1

RkJQdWJsaXNoZXIy MjY0ODMw